secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2024-06-04T23:59:59+00:00
Accession:  0000950170-24-068297
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking Therapeutics positive Phase 2b VOYAGE data: up to 75% NASH resolution with VK2809 vs 29% placebo (p=0.0001)
--------------------------------------------------------------------------------

- NASH resolution with no worsening of fibrosis: 63-75% for VK2809 groups vs 29% placebo (p<0.05 for each, combined p<0.0001).
- Fibrosis improvement ≥1 stage with no NASH worsening: 44-57% for VK2809 vs 34% placebo (p<0.05 for 5 mg and 10 mg QOD, combined p=0.03).
- Combined endpoint (NASH resolution + fibrosis improvement) achieved by 40-50% vs 20% placebo (p<0.05 for 5 mg, 10 mg QOD, combined p=0.003).
- Liver fat reduction at 52 weeks: mean relative change -37% to -55%; ≥30% reduction in 64-88% of VK2809 patients (all p<0.0001 vs placebo).
- GI adverse events similar to placebo; discontinuation rates low; LDL-C reductions of 20-25% vs placebo (p<0.01).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000095017024068297/0000950170-24-068297-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000095017024068297/vktx-20240604.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-068297

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer